Literature DB >> 29414252

Heart Failure with Preserved Ejection Fraction.

James D Gladden1, Antoine H Chaanine1, Margaret M Redfield1.   

Abstract

Heart failure (HF) is a clinical syndrome of diverse etiologies and can be associated with preserved, reduced, or mid-range ejection fraction (EF). In the community, heart failure with preserved ejection fraction (HFpEF) is emerging as the most common form of HF. There remains considerable uncertainty regarding its pathogenesis, diagnosis, and optimal therapeutic approach. Hypotheses have been advanced to explain the underlying pathophysiology responsible for HFpEF, but to date, no specific therapy based on these hypotheses has been proven to improve outcomes in HFpEF. We provide a clinically focused review of the epidemiology, clinical presentation, diagnostic approach, pathophysiology, and treatment of HFpEF.

Entities:  

Keywords:  cardiomyopathy; diastolic heart failure; hypertension; pulmonary hypertension

Mesh:

Substances:

Year:  2018        PMID: 29414252     DOI: 10.1146/annurev-med-041316-090654

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  20 in total

1.  Trajectories of Waist-to-Hip Ratio and Adverse Outcomes in Heart Failure with Mid-Range Ejection Fraction.

Authors:  Feng Gao; Jindong Wan; Banglong Xu; Xiaochen Wang; Xianhe Lin; Peijian Wang
Journal:  Obes Facts       Date:  2020-06-22       Impact factor: 3.942

Review 2.  Heart Failure with Preserved Ejection Fraction: Pathogenesis, Diagnosis, Exercise, and Medical Therapies.

Authors:  Qingyi Zhan; Wenjing Peng; Siqi Wang; Juan Gao
Journal:  J Cardiovasc Transl Res       Date:  2022-09-28       Impact factor: 3.216

3.  Left Atrial Stiffness Index Independently Predicts Exercise Intolerance and Quality of Life in Older, Obese Patients With Heart Failure With Preserved Ejection Fraction.

Authors:  Matthew J Singleton; M Benjamin Nelson; T Jake Samuel; Dalane W Kitzman; Peter Brubaker; Mark J Haykowsky; Bharathi Upadhya; Haiying Chen; Michael D Nelson
Journal:  J Card Fail       Date:  2021-11-10       Impact factor: 6.592

Review 4.  Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms.

Authors:  Johann Bauersachs; Achim Lother
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

Review 5.  Signaling cascades in the failing heart and emerging therapeutic strategies.

Authors:  Xin He; Tailai Du; Tianxin Long; Xinxue Liao; Yugang Dong; Zhan-Peng Huang
Journal:  Signal Transduct Target Ther       Date:  2022-04-23

Review 6.  The Heart Failure with Preserved Ejection Fraction Conundrum-Redefining the Problem and Finding Common Ground?

Authors:  P Iyngkaran; M C Thomas; C Neil; M Jelinek; M Cooper; J D Horowitz; D L Hare; D M Kaye
Journal:  Curr Heart Fail Rep       Date:  2020-04

Review 7.  Cellular and molecular pathobiology of heart failure with preserved ejection fraction.

Authors:  Sumita Mishra; David A Kass
Journal:  Nat Rev Cardiol       Date:  2021-01-11       Impact factor: 49.421

8.  Increased index of microcirculatory resistance in older patients with heart failure with preserved ejection fraction.

Authors:  Zhuo Xu; Hui-Ping Gu; Yang Gu; Wei Sun; Kun Yu; Xi-Wen Zhang; Xiang-Qing Kong
Journal:  J Geriatr Cardiol       Date:  2018-11       Impact factor: 3.327

9.  HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling.

Authors:  Joshua G Travers; Sara A Wennersten; Brisa Peña; Rushita A Bagchi; Harrison E Smith; Rachel A Hirsch; Lauren A Vanderlinden; Ying-Hsi Lin; Evgenia Dobrinskikh; Kimberly M Demos-Davies; Maria A Cavasin; Luisa Mestroni; Christian Steinkühler; Charles Y Lin; Steven R Houser; Kathleen C Woulfe; Maggie P Y Lam; Timothy A McKinsey
Journal:  Circulation       Date:  2021-03-08       Impact factor: 29.690

10.  Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study.

Authors:  David M Shavelle; Akshay S Desai; William T Abraham; Robert C Bourge; Nirav Raval; Lisa D Rathman; J Thomas Heywood; Rita A Jermyn; Jamie Pelzel; Orvar T Jonsson; Maria Rosa Costanzo; John D Henderson; Marie-Elena Brett; Philip B Adamson; Lynne W Stevenson
Journal:  Circ Heart Fail       Date:  2020-08-06       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.